B. Watson

Improving the clinical relevance of a mouse pregnancy model of antiretroviral toxicity; a pharmacokinetic dosing‐optimization study of current HIV antiretroviral regimens

P. Harrigan, L. Serghides, Smriti Kala, 2018, Antiviral research.

Oral administration of tipranavir with long-chain triglyceride results in moderate intestinal lymph targeting but no efficient delivery to HIV-1 reservoir in mesenteric lymph nodes.

B. Ling, P. Fischer, P. Gershkovich, 2021, International journal of pharmaceutics.

A Pharmacokinetic Dose-Optimization Study of Cabotegravir and Bictegravir in a Mouse Pregnancy Model

L. Serghides, C. Brumme, H. Mohan, 2022, Pharmaceutics.

Post-Marketing Experience with Nevirapine Extended Release (XR) Tablets: Effectiveness and Tolerability in a Population-Based Cohort in British Columbia, Canada

P. Harrigan, B. Yip, R. Hogg, 2015, Antiviral therapy.

HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study

P. Harrigan, J. Montaner, M. Harris, 2017, AIDS Research and Therapy.

A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure.

P. Harrigan, J. Montaner, L. C. Swenson, 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Efficacy and safety of “unboosting” atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF

P. Harrigan, M. Harris, M. Hull, 2017, HIV clinical trials.

Untimed Efavirenz Drug Levels After Switching From Brand to Generic Formulations: A Short Communication

P. Sereda, R. Barrios, C. Brumme, 2021, Therapeutic drug monitoring.